MAPT and Alzheimer disease: Investigations in preclinical AD models believably confirmed that numerous AD transistors (APP-CTFs, Tau, Aβ, PS1, and APOE4 mutants) impair mitochondria, and that some genetic and epigenetic modifications lead to the degeneration of mitochondria assembly and functionality.